Evidence map›Paper›PMID 39626775›Full record

ArticleOpen biology2024

Discovery and functional analysis of a novel ALPK1 variant in ROSAH syndrome.

Tom Snelling, Leo O Garnotel, Isabelle Jeru, Maud Tusseau, Laurence Cuisset, Antoinette Perlat, Geoffrey Minard, Thibaut Benquey, Yann Maucourant, Nicola T Wood and 2 more

Abstract read
In one paragraph

Article in Open biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Tocilizumab as a treatment tool for ROSAH syndrome: a case report.Journal of ophthalmic inflammation and infection · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tom SnellingMRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.ORCID 0000-0001-7577-8798
Leo O GarnotelDepartment of Ophthalmology, University Hospital of Reims, Reims, France.ORCID 0000-0003-3368-5950
Isabelle JeruDepartment of Medical Genetics, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France.
Maud TusseauCentre International de Recherche en Infectiologie, Inserm, U1111, University Claude Bernard, Lyon 1, UMR5308, ENS de Lyon, Lyon, France.
Laurence CuissetUniversité Paris Cité, Service de Médecine Génomique des Maladies de Système et D'Organe, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID 0000-0003-4007-3629
Antoinette PerlatDepartment of Internal Medicine and Clinical Immunology, Pontchaillou Hospital, Rennes, France.ORCID 0000-0002-4985-423X
Geoffrey MinardDepartment of Internal Medicine and Clinical Immunology, University Hospital of Reims, Reims, France.
Thibaut BenqueyLaboratory Eurofins Biomnis, Lyon, France.ORCID 0000-0001-8392-699X
Yann MaucourantDepartment of Ophthalmology, Pontchaillou Hospital, Rennes, France.
Nicola T WoodMRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.ORCID 0000-0002-3347-6625
Philip CohenMRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.ORCID 0000-0001-7632-9492
Alban ZieglerDepartment of Medical Genetics, University Hospital of Reims, Reims, France.ORCID 0000-0003-0287-3561

Funding

Wellcome Trust
6 · The paper itself

Abstract

Retinal dystrophy, optic nerve oedema, splenomegaly, anhidrosis and migraine headache (ROSAH) syndrome is an autosomal dominant disorder and to date is known to be caused by either the Thr237Met or Tyr254Cys variant in the protein kinase ALPK1. Here, we identify a family in which ROSAH syndrome is caused by a novel variant in which Ser277 is changed to Phe. All six patients examined display ocular inflammation and optic nerve elevation, four have retinal degeneration and four are registered blind. In contrast to wild-type ALPK1, which is activated specifically by bacterial ADP-heptose, ALPK1[Ser277Phe] is also activated by the human metabolites UDP-mannose and ADP-ribose and more strongly than the most frequent ROSAH-causing variant (ALPK1[Thr237Met]) but, unlike ALPK1[Thr237Met], ALPK1[Ser277Phe] is also activated by GDP-mannose. These observations can explain why ALPK1 variants causing ROSAH syndrome display constitutive activity in human cells. The side chains of Ser277 and Tyr254 interact in the crystal structure of ALPK1, but mutational analysis established that it is not the loss of this hydrogen bond between Ser277 and Tyr254 that alters the specificity of the ADP-heptose-binding pocket in the Ser277Phe and Tyr254Cys variants. The characterization of ALPK1 variants that cause ROSAH syndrome suggests ways in which drugs that selectively inhibit these disease-causing variants may be developed.

Indexed as

PedigreeAdultFemaleHumansMaleMiddle AgedModels, MolecularMutationProtein KinasesRetinal DystrophiesALPK1 protein, humanProtein KinasesADP-heptoseALPK1nucleotide sugarROSAHTIFAUDP-mannose

Identifiers

PMID39626775
PMCPMC11614533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.